605680-46-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Propanoic acid, 2-methyl-2-(2-pyridinyloxy)is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of novel drug molecules. Its unique structure allows for the creation of compounds with specific therapeutic properties, enhancing the range of treatments available for various medical conditions.
Used in Agrochemical Production:
In the agrochemical industry, Propanoic acid, 2-methyl-2-(2-pyridinyloxy)is utilized as a precursor in the production of pesticides and other agricultural chemicals. Its incorporation into these products can lead to the development of more effective and targeted agrochemicals, improving crop protection and yield.
Used in Materials Science:
Propanoic acid, 2-methyl-2-(2-pyridinyloxy)also finds applications in materials science, where it can be used to develop new materials with specific properties. Its unique chemical structure allows for the engineering of materials with tailored characteristics for use in various industries, such as in the creation of advanced polymers or other synthetic materials with specialized applications.

Upstream product

• 142-08-5 2-hydroxypyridin 
• 605680-44-2 benzyl 2-(2-pyridyloxy)propionate 
• 922502-04-3 benzyl 2-(2-pyridyloxy)-2-methylpropionate 

Relevant academic research and scientific papers

PRO-DRUGS OF TERTIARY ALCOHOLS

The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. In particular, compounds of the

ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.